

Symeres appoints Gabriella Gentile as Chief Operating Officer to drive transatlantic growth

Nijmegen, The Netherlands, October 01, 2025 – Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has appointed Gabriella Gentile as Chief Operating Officer (COO). This strategic addition to the executive team supports Symeres' transatlantic growth ambitions, building upon its strong foundations in existing and novel modalities.

Gabriella brings more than 25 years of international experience in the pharmaceutical, medical device, and services industries. She has held senior roles at Catalent, Roche and Aptuit, where she led major transformation programs focused on operational performance, lean methodologies, and change management.

In her new role, Gabriella will lead the transformation of global operations at Symeres, focusing on expanding capabilities across the pharmaceutical value chain from inception to investigational new drug (IND). She will apply her proven leadership to align business operations with measurable performance outcomes, reinforcing Symeres' commitment to quality and customer satisfaction.

"I'm delighted to join Symeres at this exciting time in their growth, said Gabriella Gentile, "Symeres operates under a cultural philosophy of openness and transparency, and I look forward to being part of developing new next generation therapies". She added, "I am ambitious in my expectations of how my global operational experience can positively impact Symeres' growth targets and I'm committed to delivering outstanding customer experiences. Symeres' growth trajectory makes this an exciting time to join."

Guillaume Jetten, Symeres CEO, added "I'm delighted that Gabriella has accepted this position. 'Gabriella brings a set of highly relevant skills and experience from both her background in medicinal chemistry, but also her decades of large Pharma and biotech experience that will support the future growth plans of Symeres".

Most recently, Gabriella served as global improvement director at Catalent, where she developed and implemented standardized operational frameworks across multiple sites. Prior to that, she consulted independently on global change and operational excellence programs, helping organizations improve performance and implement strategic business initiatives.

Her appointment marks another significant step in Symeres' expansion strategy, as the company positions itself as a global biotechnology leader bridging European innovation and American market presence.

About Symeres

Symeres is a leading mid-sized transatlantic Contract Research Development and Manufacturing Organization (CRDMO) for drug discovery and development operating across sites in the Netherlands, the Czech Republic, Finland, and the US. The company combines proven expertise, adaptive thinking and attentive collaboration for small molecule and other drug modalities to realize the full value of transformative therapies from inception to IND. Services span from preclinical hit finding all the way to the delivery of early clinical phase drug substance API.

www.symeres.com

Press contacts**Symeres**

Aranda Rahbarkouhi – aranda@ramarketingpr.com

RA Marketing PR